Sana Biotechnology (SANA) Enterprise Value (2021 - 2026)

Sana Biotechnology has reported Enterprise Value for 7 years, with the latest figure at -$101.1 million in Q1 2026.

• Quarterly Enterprise Value rose 3.4% year-over-year to -$101.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$101.1 million (up 3.4% YoY) and the FY2025 annual result came in at -$76.1 million, up 42.11% from the prior year.
• Enterprise Value slipped to -$101.1 million in Q1 2026 per SANA's latest filing, from -$76.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$72.7 million in Q2 2025 and troughed at -$512.4 million in Q1 2022.
• A 5-year average of -$186.1 million and a median of -$166.6 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value soared 71.93% in 2022, then sank 39.42% in 2024.
• Over 5 years, Enterprise Value stood at -$182.9 million in 2022, then climbed by 24.89% to -$137.3 million in 2023, then climbed by 4.33% to -$131.4 million in 2024, then soared by 42.11% to -$76.1 million in 2025, then plunged by 32.96% to -$101.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$101.1 million, -$76.1 million, and -$107.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.